Potential role of tocilizumab in severe gastrointestinal barrier damage after car t-cell therapy

We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.

Mots clés

tocilizumab Il-6 CAR T-cell

Domaines

Sciences du Vivant [q-bio]

Fichier principal

S1684118221000499.pdf (2.85 Mo)

Origine	Fichiers produits par l'(les) auteur(s)

Accord Elsevier CCSD : Connectez-vous pour contacter le contributeur

https://hal.univ-lille.fr/hal-03533922

Soumis le : mardi 9 mai 2023-08:44:02

Dernière modification le : mercredi 5 juin 2024-11:02:04

Archivage à long terme le : jeudi 10 août 2023-18:16:40

Dates et versions

hal-03533922 , version 1 (09-05-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

HAL Id : hal-03533922 , version 1
DOI : 10.1016/j.jmii.2021.02.006
PII : S1684-1182(21)00049-9
PUBMED : 33712404

Citer

David Beauvais, Oriane Karleskind, Severine Loridant, Remy Nyga, Marie Lamiaux, et al.. Potential role of tocilizumab in severe gastrointestinal barrier damage after car t-cell therapy. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2021, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 54 (2), pp.327-330. ⟨10.1016/j.jmii.2021.02.006⟩. ⟨hal-03533922⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM CNRS INC-CNRS UNIV-LILLE MSAP

36 Consultations

23 Téléchargements